Rakovina Therapeutics Announces Stock Option Grants

Core Insights - Rakovina Therapeutics Inc. has approved the grant of 540,000 stock options to consultants, employees, officers, and directors as part of its Long Term Incentive Plan [1] - Each stock option is exercisable for five years at a price of $0.70 per share, vesting in equal parts every six months over the next three years [2] - The company focuses on developing innovative cancer treatments using AI-powered drug discovery, specifically targeting DNA-damage response [3] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company dedicated to advancing cancer therapies through unique technologies and proprietary generative AI platforms [3] - The company aims to optimize drug candidates at a faster pace and has established a pipeline of DNA-damage response inhibitors, with plans to advance candidates into human clinical trials in collaboration with pharmaceutical partners [3]